Kymera Therapeutics, Inc. (KYMR)
NasdaqGM · USD · Healthcare · Biotechnology
$114.84 (+3.68%) as of
Key statistics
- Market cap
- 9.45B
- Forward P/E
- -22.53
- EPS (TTM)
- -3.25
- Dividend yield
- 0.00%
- 52-week range
- 55.66 – 130.05
- Beta
- 1.98
- Revenue (TTM)
- 105M
- Profit margin
- -285.33%
- Analyst target
- $139.35
- Volume
- 438.50k
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Watertown, MA, United States
- Employees
- 273
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.